Urinary peptide panel for prognostic assessment of bladder cancer relapse

Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently needed to guide clinical intervention. As a follow-up to the previously published study on CE-MS-based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information regarding the relapse status were investigated. The peptidomics dataset (n = 98) was split into training and test set. Cox regression was utilized for feature selection in the training set. Investigation of the entire training set at the single peptide level revealed 36 peptides being strong independent prognostic markers of disease relapse. Those features were further integrated into a Random Forest-based model evaluating the risk of relapse for BC patients. Performance of the model was assessed in the test cohort, showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse highlighting the need for its incorporation in prospective studies to establish its value in the clinical management of BC.

[1]  R. C. Macridis.  A review , 1963 .

[2]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[3]  H. Grossman,et al.  The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. , 2000, The Urologic clinics of North America.

[4]  L. Kiemeney,et al.  Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. , 2004, European urology.

[5]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[6]  G. Georgiev,et al.  Peptidoglycan Recognition Protein Tag7 Forms a Cytotoxic Complex with Heat Shock Protein 70 in Solution and in Lymphocytes* , 2004, Journal of Biological Chemistry.

[7]  W. Kolch,et al.  Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. , 2004, Rapid communications in mass spectrometry : RCM.

[8]  J. Revillard,et al.  Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma , 2004, Urological Research.

[9]  Helen Kim,et al.  The case for well-conducted experiments to validate statistical protocols for 2D gels: different pre-processing = different lists of significant proteins , 2005, BMC biotechnology.

[10]  H. Mischak,et al.  Biomarker discovery by CE‐MS enables sequence analysis via MS/MS with platform‐independent separation , 2006, Electrophoresis.

[11]  H. Frierson,et al.  Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. , 2006, The Lancet. Oncology.

[12]  A. Dominiczak,et al.  CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics , 2008, Proteomics. Clinical applications.

[13]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[14]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[15]  A. Vlahou,et al.  Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics , 2009, Clinical Cancer Research.

[16]  H. Mischak,et al.  Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. , 2009, Journal of proteome research.

[17]  Y. Xuan,et al.  Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder , 2010, Journal of Cancer Research and Clinical Oncology.

[18]  P. Zürbig,et al.  Human urinary peptide database for multiple disease biomarker discovery , 2011, Proteomics. Clinical applications.

[19]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[20]  Yong Wang,et al.  A novel differential diagnostic model based on multiple biological parameters for immunoglobulin A nephropathy , 2012, BMC Medical Informatics and Decision Making.

[21]  Yan Li,et al.  Collagen as a double-edged sword in tumor progression , 2013, Tumor Biology.

[22]  J. Catto,et al.  EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients , 2013, Central European journal of urology.

[23]  Y. Lotan,et al.  Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder , 2013, British Journal of Cancer.

[24]  H. Mischak,et al.  CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis , 2013, PloS one.

[25]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[26]  T. Downs,et al.  Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma , 2013, PloS one.

[27]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[28]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[29]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[30]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[31]  K. Tsui,et al.  Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer* , 2015, Molecular & Cellular Proteomics.

[32]  C. Pan,et al.  SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor , 2015, Clinical Cancer Research.

[33]  M. Dew,et al.  A Prospective Analysis , 2015 .

[34]  C. Pan,et al.  SH 3 BGRL 3 Protein As A Potential Prognostic Biomarker For Urothelial Carcinoma : A novel binding partner of epidermal growth factor receptor , 2015 .

[35]  L. Collette,et al.  EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. , 2016, European urology.

[36]  A. Vlahou,et al.  Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study , 2016, Clinical Cancer Research.

[37]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[38]  Baojing Ma,et al.  Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer , 2016, OncoTargets and therapy.

[39]  M. Harpole,et al.  Current state of the art for enhancing urine biomarker discovery , 2016, Expert review of proteomics.

[40]  N. Wang,et al.  Development of diagnostic model of lung cancer based on multiple tumor markers and data mining , 2017, Oncotarget.

[41]  A. Vlahou,et al.  Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention , 2017, Oncotarget.

[42]  A. Vlahou,et al.  Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention , 2017, Oncotarget.

[43]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[44]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[45]  J. Lloreta,et al.  FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. , 2017, Human pathology.

[46]  Kentaro Inamura,et al.  Bladder Cancer: New Insights into Its Molecular Pathology , 2018, Cancers.

[47]  Tianxin Lin,et al.  The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1 , 2018, Cell Death & Disease.

[48]  Y. Fujii.  Prediction models for progression of non‐muscle‐invasive bladder cancer: A review , 2018, International journal of urology : official journal of the Japanese Urological Association.

[49]  K. Scotlandi,et al.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors , 2018, Genes.

[50]  Z. Yao,et al.  Identification of Alzheimer's Disease and Mild Cognitive Impairment Using Networks Constructed Based on Multiple Morphological Brain Features. , 2018, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[51]  T. Tan,et al.  Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. , 2019, European urology.

[52]  M. Terris,et al.  Large‐scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival , 2019, Cancer.

[53]  A. Vlahou,et al.  Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer , 2019, Proteomics. Clinical applications.

[54]  M. Terris,et al.  Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival , 2019, Cancer Epidemiology, Biomarkers & Prevention.